Up-regulation of histone deacetylase 6 is associated with the malignancy of melanoma and the prognosis of patients

Defu Medical Publishing House published a new article in the Journal of Cancer Management and Research.
Up-regulation of histone deacetylase 6 is related to the malignant degree of melanoma and the prognosis of patients.

Abstract Background: Melanoma is the most malignant skin tumor, and its morbidity and mortality are increasing year by year.

In recent years, more and more researchers have devoted themselves to exploring the biological characteristics of melanoma, but there are no clinical biomarkers that can predict the occurrence and development of melanoma.

Histone deacetylase 6 (HDAC6) has been shown to be a prognostic biomarker in a variety of cancers.

In this study, we aimed to explore the predictive value of HDAC6 on the prognosis of patients with skin melanoma.

Methods: 80 cases of skin melanoma patients were enrolled in this study.

Detect the protein level and mRNA expression level of HDAC6, and analyze the relationship between the expression of HDAC6 and the clinical characteristics and survival time of patients with skin melanoma.

Results: The results showed that the high expression of HDAC6 was significantly related to poor clinicopathological characteristics.

The high expression of HDAC6 is associated with metastasis of melanoma, and it is also associated with a reduction in the survival time of patients with melanoma.

Conclusion: The expression level of HDAC6 can be used as a biomarker to predict the prognosis of patients with skin melanoma.

Keywords: HDAC6; skin melanoma; prognostic biomarkers; survival rate; metastasis